2022
Associations of medication with subcortical morphology across the lifespan in OCD: Results from the international ENIGMA Consortium
Ivanov I, Boedhoe PSW, Abe Y, Alonso P, Ameis SH, Arnold PD, Balachander S, Baker JT, Banaj N, Bargalló N, Batistuzzo MC, Benedetti F, Beucke JC, Bollettini I, Brem S, Brennan BP, Buitelaar J, Calvo R, Cheng Y, Cho KIK, Dallaspezia S, Denys D, Diniz JB, Ely BA, Feusner JD, Ferreira S, Fitzgerald KD, Fontaine M, Gruner P, Hanna GL, Hirano Y, Hoexter MQ, Huyser C, Ikari K, James A, Jaspers-Fayer F, Jiang H, Kathmann N, Kaufmann C, Kim M, Koch K, Kwon JS, Lázaro L, Liu Y, Lochner C, Marsh R, Martínez-Zalacaín I, Mataix-Cols D, Menchón JM, Minuzzi L, Morer A, Morgado P, Nakagawa A, Nakamae T, Nakao T, Narayanaswamy JC, Nurmi EL, Oh S, Perriello C, Piacentini JC, Picó-Pérez M, Piras F, Piras F, Reddy YCJ, Manrique DR, Sakai Y, Shimizu E, Simpson HB, Soreni N, Soriano-Mas C, Spalletta G, Stern ER, Stevens MC, Stewart SE, Szeszko PR, Tolin DF, van Rooij D, Veltman DJ, van der Werf YD, van Wingen GA, Venkatasubramanian G, Walitza S, Wang Z, Watanabe A, Wolters LH, Xu X, Yun JY, Zarei M, Zhang F, Zhao Q, Jahanshad N, Thomopoulos SI, Thompson PM, Stein DJ, van den Heuvel OA, O'Neill J, Group T, Poletti S, Fridgeirsson E, Ikuta T, de Wit S, Vriend C, Kasprzak S, Kuno M, Takahashi J, Miguel E, Shavitt R, Hough M, Pariente J, Ortiz A, Bertolín S, Real E, Segalàs C, Moreira P, Sousa N, Narumoto J, Yamada K, Tang J, Fouche J, Kim T, Choi S, Ha M, Park S. Associations of medication with subcortical morphology across the lifespan in OCD: Results from the international ENIGMA Consortium. Journal Of Affective Disorders 2022, 318: 204-216. PMID: 36041582, DOI: 10.1016/j.jad.2022.08.084.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderUnmedicated patientsOlder adultsAssociation of medicationVolumes of putamenSubcortical brain structuresReuptake inhibitorsVentricular hypertrophyHippocampal atrophyMedicated patientsPsychotropic medicationsTherapeutic responseHippocampal volumeStriatal volumeSubcortical nucleiPatientsPsychotic disordersAntipsychoticsSubcortical morphologyStructural MRINormal agingBrain structuresBenzodiazepinesOCD patientsENIGMA consortium
2019
Treatments used for obsessive–compulsive disorder—An international perspective
Brakoulias V, Starcevic V, Albert U, Arumugham S, Bailey B, Belloch A, Borda T, Dell'Osso L, Elias J, Falkenstein M, Ferrao Y, Fontenelle L, Jelinek L, Kalogeraki L, Kay B, Laurito L, Lochner C, Maina G, Marazziti D, Martin A, Matsunaga H, Miguel E, Morgado P, Mourikis I, Pasquini M, Rivera R, Potluri S, Reddy J, Riemann B, do Rosario M, Shavitt R, Stein D, Viswasam K, Wang Z, Fineberg N. Treatments used for obsessive–compulsive disorder—An international perspective. Human Psychopharmacology Clinical And Experimental 2019, 34: e2686. PMID: 30628745, DOI: 10.1002/hup.2686.Peer-Reviewed Original Research
2016
NEUROPSYCHOLOGICAL PREDICTORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIORAL GROUP THERAPY IN OBSESSIVE–COMPULSIVE DISORDER
Braga D, Abramovitch A, Fontenelle L, Ferrão Y, Gomes J, Vivan A, Ecker K, Bortoncello C, Mittelman A, Miguel E, Trentini C, Cordioli A. NEUROPSYCHOLOGICAL PREDICTORS OF TREATMENT RESPONSE TO COGNITIVE BEHAVIORAL GROUP THERAPY IN OBSESSIVE–COMPULSIVE DISORDER. Depression And Anxiety 2016, 33: 848-861. PMID: 27100799, DOI: 10.1002/da.22509.Peer-Reviewed Original ResearchConceptsCognitive-behavioral group therapyObsessive-compulsive disorderBehavioral group therapyNeuropsychological test performanceTest performanceNeuropsychological domainsCBGT groupGroup therapyOCD patientsNeuropsychological outcome measuresNeuropsychological predictorsNeuropsychological functioningNeuropsychological measuresOCD symptomsNeurocognitive functionDepression symptomsTreatment respondersTreatment responseParticipantsAvailable researchInconsistent resultsDisordersPredictorsAnxietyMeasuresUse of benzodiazepines in obsessive–compulsive disorder
Starcevic V, Berle D, do Rosário M, Brakoulias V, Ferrão Y, Viswasam K, Shavitt R, Miguel E, Fontenelle L. Use of benzodiazepines in obsessive–compulsive disorder. International Clinical Psychopharmacology 2016, 31: 27-33. PMID: 26426443, DOI: 10.1097/yic.0000000000000100.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Anxiety AgentsAnxietyBenzodiazepinesCross-Sectional StudiesDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSocioeconomic FactorsConceptsObsessive-compulsive disorderBDZ useOCD patientsUse of benzodiazepinesTreatment of OCDBrazilian Research ConsortiumAdditional medicationTreatment guidelinesMulticentre studyReuptake inhibitorsObsessive-compulsive spectrum disordersBenzodiazepine useMarked anxietyPatientsMedicationsBDZDisordersResearch ConsortiumCurrent age